One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 350,000 shares of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) on Wednesday, as the share price of this fund traded relatively flat in the day’s session. Its share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 366,228 shares of Takeda. At Wednesday’s closing price, this would have valued this sale at roughly $6.2 million. This is only a small fraction of the total holdings. This fund is up 84% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
|ARKF||TCSLI||TCS GROUP HOLDING PLC||35,354|
|ARKG||PSTI||PLURISTEM THERAPEUTICS INC||1,357|
|ARKG||SRPT||SAREPTA THERAPEUTICS INC||22,178|
|ARKG||TAK||TAKEDA PHARMACEUTICAL CO LTD||366,228|
|ARKQ||GLEO||GALILEO ACQUISITION CORP||325,800|
|ARKQ||RAVN||RAVEN INDUSTRIES INC||12,814|
|ARKQ||TCEHY||TENCENT HOLDINGS LTD||36,315|
|ARKW||TCEHY||TENCENT HOLDINGS LTD||46,793|
|ARKW||PSTG||PURE STORAGE INC||187,131|
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.